Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213800 | 0.87 | RORC (0.43) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL16886253 | 0.84 | RORC (0.44) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL18213832 | 0.82 | AR (0.41) | AR | |
| SCHEMBL552171 | 0.81 | TDP1 (0.42) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL3751942 | 0.79 | KDM4E (0.43) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL18213802 | 0.78 | HTR2C (0.43) | RORCHTR2AHTR2C | |
| SCHEMBL20817916 | 0.77 | MPO (0.38) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL3748708 | 0.76 | AR (0.42) | RORCPGRNR3C1NR3C2AR | |
| SCHEMBL18213796 | 0.76 | ALDH1A1 (0.43) | FFAR1MAOB | |
| SCHEMBL2591940 | 0.75 | SLC22A12 (0.43) | PGRARFFAR1FFAR4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771320-B2 | Carbocyclic sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771320-B2 | Carbocyclic sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | BRISTROL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | RORC, RORB, RORA | RORC 1/4885PGR 2863/4885NR3C1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.